Bibliographys
- RIECKMANN P, O'CONNOR P, FRANCIS G et al.: Haematological effects of interferon I3-la (Rebif®) therapy in multiple sclerosis. (In press).
- WOLINSKY JS, TOYKA KV, KAPPOS L, GROSSBERG SE: Interferon-I3 antibodies: implications for the treatment of MS. Lancet Neurol (2003) 2(9):528.
- •A report of a meeting reviewing the clinical significance of NAbs during IFN-13-la therapy.
- ANTONETTI F, FINOCCHIARO 0, MASCIA M, TERLIZZESE MG, JABER A: A comparison of the biologic activity of two recombinant IFN-I3 preparations used in the treatment of relapsing-remitting multiple sclerosis. Interferon Cytokine Res. (2002) 22(12):1181–1184.
- GIOVANNONI G, MUNSCHAUER FE III, DEISENHAMMER F: Neutralising antibodies to interferon 13 during the treatment of multiple sclerosis. Neurol. Neurosurg. Psychiatr. (2002) 73(5):465–469.
- IFN-I3 MULTIPLE SCLEROSIS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: Neutralizing antibodies during treatment of multiple sclerosis with interferon 13-1b: experience during the first three years. Neurology (1996) 47:889–894.
- RUDICK R, SIMONIAN N, ALAM J et al.: Incidence and significance of neutralizing antibodies to interferon 13-lain multiple sclerosis. Neurology (1998) 50:1266–1272.
- SORENSEN PS, ROSS C, CLEMMESEN KM et al: Clinical importance of neutralising antibodies against interferon 13 in patients with relapsing-remitting multiple sclerosis. Lancet (2003) 362(9391):1184–1191.
- •Population-based assessment of the effect of NAbs on clinical outcomes in RRMS patients treated with IFN-I3.
- POLMAN C, KAPPOS L, WHITE R et al.: Neutralizing antibodies during treatment of secondary progressive MS with interferon 13-1b. Neurology (2003) 60(1)37–43.
- WEINSHENKER BG: The natural history of multiple sclerosis. Neurol. Clin. (1995) 13(1):119–146.
- ARNOLDUS JH, KILLESTEIN J, PFENNINGS LE et al.: Quality of life during the first 6 months of interferon-I3 treatment in patients with MS. Malt. Stier. (2000) 6(5):338–342.
- ZEUZEM S, FEINMAN SV, RASENACK J et al.: Peginterferon a-2a in patients with chronic hepatitis C. N Engl. Med. (2000) 343(23):1666–1672.
- PEPINSKY RB, LEPAGE DJ, GILL A et al.: Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-13-la with preserved in vitro bioactivity. Pharinacol. Exp. Ther. (2001) 297(3):1059–1066.
- GOGGIN T, VIGNA E, NEUTEBOOM B, TRINCHARD-LUGAN I, KLETZL H: Non-covalent complex of interferon-I3- la and recombinant human Type I interferon receptor subunit 2a: preclinical and Phase I results. Malt. Scler. (2003) 9\(Suppl. 1):S138. Abstract P553.
- MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl. I Med. (2003) 348(1):15–23.
Websites
- http://www.fda.gov/cder/foi/labe1/2003/ IFNbchi031403LB.pdf Betaseron® product label providing data on study outcomes (2003).
- http://www.fda.gov/cder/biologics/ products/ifnbser030702.htm Review of clinical trial data of IFN-I3-la (Rebe) by FDA (2002).
- http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/beta-interferon_hpc_e.pdf Health Canada letter regarding liver dysfunction with IFN-I3 products (2004).
- http://www.fda.gov/cder/biologics/ products/IFNbbio051796.htm Summary basis of approval. FDA official document for license of interferon 13-la (Avonex9 (1995).